Cargando…

Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes

BACKGROUND: EDC1 is a novel type of antibody-drug conjugate which binds and inhibits the Na,K-ATPase on the surface of cancer cells expressing dysadherin. The purpose of this study was to determine the expression of dysadherin in different types of thyroid carcinoma, and evaluate the therapeutic pot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Samuel, Yu, Xiao-Min, Montemayor-Garcia, Celina, Ahmed, Kamal, Weinlander, Eric, Lloyd, Ricardo V., Dammalapati, Ajitha, Marshall, David, Prudent, James R., Chen, Herbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421862/ https://www.ncbi.nlm.nih.gov/pubmed/28160550 http://dx.doi.org/10.18632/oncotarget.14904

Ejemplares similares

Dysadherin awakens mechanical forces and promotes colorectal cancer progression
por: Park, So-Yeon, et al.
Publicado: (2022)

Prognostic significance of dysadherin expression in advanced colorectal carcinoma
por: Aoki, S, et al.
Publicado: (2003)

Involvement of dysadherin and E-cadherin in the development of testicular tumours
por: Batistatou, A, et al.
Publicado: (2005)

In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin
por: Batistatou, A, et al.
Publicado: (2007)

Prognostic value of dysadherin in cancer: A systematic review and meta-analysis
por: Niinivirta, Aino, et al.
Publicado: (2022)

Prognostic and Clinicopathological Significance of EphB3 and Dysadherin Expression in Extrahepatic Cholangiocarcinoma
por: Wu, Zhengchun, et al.
Publicado: (2020)

Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line
por: Tesfazghi, Sara, et al.
Publicado: (2013)

FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways
por: Besso, María José, et al.
Publicado: (2019)

Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo
por: Jang, Samuel, et al.
Publicado: (2017)

FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients
por: Tassi, Renata A., et al.
Publicado: (2019)

Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivo
por: Wyche, Thomas P., et al.
Publicado: (2014)

Faulty Metabolism: A Potential Instigator of an Aggressive Phenotype in Cdk5-dependent Medullary Thyroid Carcinoma
por: Gupta, Priyanka, et al.
Publicado: (2023)

Aberrantly regulated dysadherin and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances tumorigenesis and DNA targeting drug resistance of liver cancer stem cells
por: JIANG, NAN, et al.
Publicado: (2015)

An aggressive and expanded phenotype in a kindred with a c.57delG SDHD mutation
por: Caetano, Celina, et al.
Publicado: (2021)

Epigenetic silencing of HOPX is critically involved in aggressive phenotypes and patient prognosis in papillary thyroid cancer
por: Ooizumi, Yosuke, et al.
Publicado: (2019)

Impact of Mind–Body Medicine Professional Skills Training on Healthcare Professional Burnout
por: Weinlander, Eva Elisabeth, et al.
Publicado: (2020)

Molecular features of aggressive thyroid cancer
por: Elia, Giusy, et al.
Publicado: (2022)

The Glycolytic Phenotype is Correlated with Aggressiveness and Poor Prognosis in Invasive Ductal Carcinomas
por: Jang, Se Min, et al.
Publicado: (2012)

Is an aggressive approach justified in the management of an aggressive cancer-the squamous cell carcinoma of thyroid?
por: Chintamani, et al.
Publicado: (2007)

Molecular Targeted Therapies of Aggressive Thyroid Cancer
por: Ferrari, Silvia Martina, et al.
Publicado: (2015)

OR19-3 Differential Interactions of Vitamin D Binding Protein and Vitamin D Receptor in Different Ethnic Groups with Aggressive Thyroid Cancer
por: Gray, Austin, et al.
Publicado: (2022)

CD44 Is Associated with the Aggressive Phenotype of Nasopharyngeal Carcinoma through Redox Regulation
por: Lin, Chien-Hung, et al.
Publicado: (2013)

microRNA-564 inhibits the aggressive phenotypes of papillary thyroid cancer by directly targeting astrocyte-elevated gene-1
por: Song, Zhenzhen, et al.
Publicado: (2019)

The indices of body size and aggressiveness of papillary thyroid carcinoma
por: Kim, Ju-Yeon, et al.
Publicado: (2011)

Molecular Pathways Associated with Aggressiveness of Papillary Thyroid Cancer
por: Benvenga, Salvatore, et al.
Publicado: (2014)

Management of the Patient with Aggressive and Resistant Papillary Thyroid Carcinoma
por: Miftari, Rame, et al.
Publicado: (2016)

Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness
por: Revilla, Giovanna, et al.
Publicado: (2019)

Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas
por: Jin, Meihua, et al.
Publicado: (2021)

Aggressive Papillary Thyroid Carcinoma Presenting with Metastasis to the Pancreas
por: Warda, Firas, et al.
Publicado: (2022)

Catalase Overexpression Drives an Aggressive Phenotype in Glioblastoma
por: Flor, Susanne, et al.
Publicado: (2021)

Aggressive phenotype editing by modulated immune cells
por: Markova, E., et al.
Publicado: (2022)

microRNA-564 Inhibits the Aggressive Phenotypes of Papillary Thyroid Cancer by Directly Targeting Astrocyte-Elevated Gene-1 [Retraction]
Publicado: (2021)

Applying Metabolomics to Understand the Aggressive Phenotype and Identify Novel Therapeutic Targets in Glioblastoma
por: Ahmed, Kamran A., et al.
Publicado: (2014)

Conservation in Mammals of Genes Associated with Aggression-Related Behavioral Phenotypes in Honey Bees
por: Liu, Hui, et al.
Publicado: (2016)

Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness
por: Williams, E D, et al.
Publicado: (2004)

Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas
por: Cunha, Lucas Leite, et al.
Publicado: (2012)

Biotinidase is a Novel Marker for Papillary Thyroid Cancer Aggressiveness
por: So, Anthony K.-C., et al.
Publicado: (2012)

LGR5 is associated with tumor aggressiveness in papillary thyroid cancer
por: Michelotti, Gregory, et al.
Publicado: (2015)

Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma
por: Teng, Huajing, et al.
Publicado: (2018)

Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers
por: Mady, Leila J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v61bo7sdrghag9gbenroc6j8q7